Our in silico analyses screened existing FDA-approved drugs and identified compounds like, Valproic Acid (a histone deacetylase- HDAC inhibitor), Gemfibrozil (a lipoprotein lipase inhibitor and PPAR agonist), and atypical psychotropic drugs like Doxylamine (an antihistamine) and Diprophylline (an adenosine receptor antagonist) as probable potential therapeutic alternatives for GBM. The gene discussed is LPL; the disease is glioblastoma.